Testosterone replacement therapy improves erectile function in men with confirmed hypogonadism, but it is not a universal treatment for erectile dysfunction. Clinical evidence shows that TRT restores erectile function reliably in men whose ED is caused by testosterone deficiency. In men with normal testosterone, TRT adds little benefit. The key clinical question is not whether testosterone fixes ED, but whether testosterone deficiency is contributing to the ED in a specific patient. That determination requires laboratory evaluation, not assumption.
How Testosterone Affects Erectile Function
Testosterone does not directly cause erections, but it plays an essential role in maintaining the biological infrastructure that makes erections possible. Understanding this mechanism clarifies both why testosterone deficiency causes ED and why TRT restores function in hypogonadal men.
The penile vascular mechanism
Erections depend on smooth muscle relaxation in the corpora cavernosa, which allows arterial inflow and vascular engorgement. This relaxation is mediated by nitric oxide (NO), produced by endothelial cells and nerve terminals in penile tissue. Testosterone upregulates nitric oxide synthase (NOS) expression and activity in the penile vasculature. When testosterone falls, NOS activity decreases, nitric oxide production is impaired, and smooth muscle relaxation is insufficient for full engorgement.
Low testosterone is also associated with increased PDE5 activity (phosphodiesterase type 5, the enzyme that breaks down cyclic GMP and terminates erections). This dual effect of reduced NO production and accelerated cGMP breakdown means hypogonadal men have impaired erectile initiation and maintenance through the same pathway that PDE5 inhibitors (sildenafil, tadalafil) target.
The central nervous system mechanism
Beyond penile vascular effects, testosterone acts centrally on the hypothalamus and limbic system to drive sexual motivation and arousal. Androgen receptors in these regions respond to circulating testosterone by generating spontaneous erotic thoughts, morning erections, and sexual interest that primes the erectile response. Low testosterone suppresses this central drive, meaning the problem is upstream of the physical erectile mechanism. This is why hypogonadal men with ED often notice the loss of morning and spontaneous erections before they notice erectile failure during sexual activity.
The first is central: loss of libido and spontaneous erections from suppressed hypothalamic androgen signaling. The second is peripheral: impaired penile vascular response from reduced NOS activity and endothelial dysfunction. Hypogonadal men typically have both. TRT addresses both mechanisms simultaneously, which is why its benefit for ED in testosterone-deficient men goes beyond what PDE5 inhibitors alone can achieve.
What the Clinical Evidence Shows
The evidence for TRT in ED is well-established in hypogonadal men but does not support its use in men with normal testosterone. The distinction is important and consistently supported across the major trials and meta-analyses.
Key evidence in hypogonadal men
A 2005 meta-analysis by Isidori et al. in the European Journal of Endocrinology pooled data from randomized controlled trials and found that testosterone therapy significantly improved erectile function, sexual satisfaction, and morning erections in hypogonadal men compared to placebo. The overall response rate for erectile function improvement was approximately 63%. Importantly, the benefit was substantially smaller in men with normal or borderline testosterone levels.
The Testosterone Trials (TTrials, NEJM 2016), which enrolled 790 hypogonadal men aged 65 and older, included a sexual function sub-study demonstrating statistically significant improvements in erectile function scores, libido, and sexual activity frequency compared to placebo at 12 months. These were men with confirmed testosterone below 275 ng/dL.
TRT and PDE5 inhibitor combination
A clinically important finding from multiple studies is that hypogonadal men who fail to respond adequately to PDE5 inhibitors (sildenafil, tadalafil, vardenafil) often respond when TRT is added. Testosterone appears to restore the penile vascular responsiveness to PDE5 inhibition by normalizing NOS expression and endothelial function. A 2004 study by Shabsigh et al. found that 72% of hypogonadal men who did not respond to sildenafil alone achieved satisfactory erectile function after testosterone was added. This finding has significant clinical implications: men labeled as “PDE5 inhibitor non-responders” should have testosterone measured before being considered for more invasive interventions.
Other Causes of ED That Must Be Ruled Out
Testosterone deficiency is one cause of ED but rarely the only one. A complete diagnostic workup identifies all contributing factors, because treating testosterone alone may produce incomplete recovery if vascular, neurological, or psychological contributors are not addressed.
Common Causes of Erectile Dysfunction: Where Testosterone Fits
Most men with ED have multiple contributing factors. Testosterone deficiency coexists with vascular disease in many cases. Both require assessment.
The clinical implication is straightforward: all men presenting with ED should have testosterone measured as part of the initial workup. The finding of hypogonadism does not eliminate the need to evaluate cardiovascular risk, as low testosterone and vascular disease frequently co-exist and compound each other. A man with both low testosterone and endothelial dysfunction will likely need both TRT and PDE5 inhibitor therapy, plus cardiovascular risk management.
The Diagnostic Workup: What Labs to Request
A systematic evaluation of ED that includes hormonal assessment identifies the treatable endocrine components and guides the most effective treatment approach.
| Test | Why It Matters for ED | Action Threshold |
|---|---|---|
| Total Testosterone 8 to 10 AM, fasting, two draws |
Primary hormonal marker. Confirms or rules out hypogonadism as ED contributor. | Below 300 ng/dL on two draws = confirmed hypogonadism |
| Free Testosterone | Men with high SHBG may have symptomatic deficiency despite borderline total T. | Below 5 to 9 pg/mL (lab-dependent) |
| LH and FSH | Distinguishes primary from secondary hypogonadism. Guides treatment choice. | Low LH with low T = secondary; evaluate pituitary |
| Prolactin | Hyperprolactinemia suppresses testosterone and causes ED independently. | Above 20 ng/mL warrants MRI pituitary |
| TSH | Hypothyroidism causes ED and low libido independently of testosterone. | Above 4.0 mIU/L requires follow-up |
| Fasting glucose and HbA1c | Diabetes is the leading cause of vascular and neurogenic ED. Low T and diabetes coexist. | HbA1c above 5.7% indicates prediabetes; above 6.5% is diagnostic |
| Lipid panel and blood pressure | ED is a cardiovascular risk marker. Endothelial dysfunction affects both penile and coronary arteries. | Any abnormality warrants cardiovascular risk stratification |
Penile arteries are smaller than coronary arteries and manifest endothelial dysfunction earlier. Men presenting with new-onset ED, particularly those under 60 without obvious psychological causes, should be evaluated for cardiovascular risk. Studies by Montorsi et al. (2003) found that ED precedes coronary artery disease by 3 years on average in men who subsequently develop cardiac events. An ED workup is therefore not only a urological evaluation but a cardiovascular risk assessment.
TRT Formulations for Men With ED: Practical Considerations
If testosterone deficiency is confirmed and TRT is initiated, the choice of delivery method affects how quickly erectile function improves and how stable the hormonal environment is during recovery.
Injectable testosterone
Weekly or biweekly intramuscular or subcutaneous injections of testosterone cypionate or enanthate produce predictable peaks and troughs. The peak in the first 2 to 3 days post-injection may produce supraphysiologic testosterone, which can temporarily convert to estradiol via aromatase, potentially impairing rather than improving erectile function until levels stabilize. Men sensitive to estradiol fluctuation may notice variable erectile quality during the injection cycle. Adjusting to subcutaneous injection and optimizing the injection interval can minimize this variation.
Transdermal gels and creams
Daily application of testosterone gel or cream produces stable, consistent testosterone levels without the peak-trough cycle of injections. For men whose erectile dysfunction is particularly sensitive to hormonal fluctuation, stable daily delivery often produces more consistent erectile improvement than weekly injections. Transfer to partners is a practical concern requiring application-site hygiene.
Subcutaneous pellets
Pellets inserted every 3 to 6 months provide the most stable testosterone delivery. After an initial peak in the first few weeks, levels plateau and remain consistent until pellet dissolution. This stability can benefit erectile function in men who are sensitive to hormonal variation, but the long duration makes dose adjustment impossible if adverse effects occur.
Testosterone aromatizes to estradiol, and both excessively high and excessively low estradiol can impair erectile function. Optimal estradiol for erectile function is generally in the range of 20 to 30 pg/mL. Men who aromatize aggressively may need low-dose aromatase inhibitor management under physician supervision. Men taking aromatase inhibitors without evidence of elevated estradiol may suppress estradiol too far, worsening ED. Estradiol should be measured at baseline and monitored during TRT optimization.
TRT Combined With PDE5 Inhibitors: When Both Are Needed
For many hypogonadal men with ED, TRT alone is sufficient to restore satisfactory erectile function. For others, particularly those with co-existing vascular disease or diabetes, TRT normalizes the hormonal component but the vascular component still requires pharmacologic support.
The combination of TRT and a PDE5 inhibitor (sildenafil, tadalafil, or vardenafil) is well-supported by clinical evidence and produces additive benefit. TRT restores NOS expression and endothelial responsiveness; PDE5 inhibition then prevents cGMP breakdown and sustains the erectile response. Men who failed PDE5 inhibitors as monotherapy while testosterone was low frequently respond to the same PDE5 inhibitor after testosterone is normalized.
ED Treatment Pathway: Where TRT Fits
What to Expect: Realistic Timeline for Erectile Improvement on TRT
Setting accurate expectations prevents premature discontinuation during the period before full benefit is established.
Weeks 1 to 4: Testosterone levels rise toward the therapeutic range. Some men notice early improvements in libido and morning erections within the first 2 to 3 weeks. Erectile function during sexual activity typically lags behind libido recovery by several weeks.
Weeks 4 to 12: The majority of the erectile function improvement attributable to testosterone occurs during this period. Spontaneous erections become more frequent. Penile sensitivity and engorgement quality improve. Men with co-existing vascular disease may notice less improvement than those with primarily hormonal ED.
Month 3 onwards: The 3-month mark is the standard clinical assessment point. At this point testosterone levels are stable, the vascular and neurological adaptations to restored testosterone have had time to develop, and a meaningful assessment of TRT’s contribution to erectile function is possible. If significant ED persists at 3 months with confirmed testosterone normalization, additional causes should be investigated.
Performance anxiety, relationship stress, and depression can maintain erectile dysfunction even after testosterone is normalized. These factors do not mean TRT is failing; they mean additional support is needed. Men with significant psychological contributors to their ED benefit from concurrent psychosexual therapy or cognitive behavioral approaches alongside TRT. The biological restoration that TRT provides creates the foundation, but psychological barriers may still need to be addressed directly. For more on the connection between testosterone and mental health, see our article on depression and low testosterone: the hidden connection.
When TRT Is Not Appropriate for ED
Testosterone therapy is not appropriate in all men with erectile dysfunction. The following situations require different approaches.
Normal testosterone levels: Men with total testosterone consistently above 400 ng/dL and ED do not have testosterone deficiency as a contributing factor. TRT in eugonadal men does not reliably improve erectile function and introduces hormonal risks without a clinical rationale. In these men, PDE5 inhibitors, cardiovascular risk management, and psychosexual assessment are the appropriate treatments.
Active prostate cancer: TRT is contraindicated in men with active prostate cancer. Men with a history of treated prostate cancer require individualized risk-benefit assessment with a urologist before TRT is considered.
Severe polycythemia: Hematocrit above 54% is a contraindication to TRT initiation. Men with elevated baseline hematocrit require monitoring and may need to address polycythemia before starting therapy.
Fertility preservation as a priority: TRT suppresses spermatogenesis. Men seeking to conceive require fertility-preserving alternatives such as clomiphene citrate or hCG rather than exogenous testosterone.
For a comprehensive overview of signs that may indicate testosterone deficiency before considering any treatment, see our guide on 15 signs of low testosterone in men.
Get Evaluated: Start With a Clinical Consultation
If you are experiencing erectile dysfunction alongside other symptoms consistent with low testosterone, a comprehensive hormonal evaluation is the appropriate starting point. Advanced TRT Clinic provides physician-supervised testosterone evaluation and treatment via telemedicine, including lab coordination, clinical interpretation, and ongoing management. Availability varies by state.
